Literature DB >> 15793118

Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B.

M Simitsopoulou1, E Roilides, J Dotis, M Dalakiouridou, F Dudkova, E Andreadou, T J Walsh.   

Abstract

The immunomodulatory effects of liposomal amphotericin B (LAMB), amphotericin B lipid complex (ABLC), and amphotericin B colloidal dispersion (ABCD) on mRNA and protein profiles of five cytokines and chemokines expressed by human monocyte-enriched mononuclear leukocytes (MNCs) were comprehensively evaluated by semiquantitative reverse transcription-PCR and enzyme-linked immunosorbent assays; they were compared to those of deoxycholate amphotericin B (DAMB). mRNAs of interleukin-1beta (IL-1beta), IL-1 receptor antagonist (IL-1ra), tumor necrosis factor alpha (TNF-alpha), monocyte chemotactic protein 1 (MCP-1), and macrophage inflammatory protein 1beta (MIP-1beta) were assessed after treatment of MNCs with each drug for 0.5, 2, 6, and 22 h. The cytokine protein profiles were obtained after incubation of MNCs with the drugs for 2 h (TNF-alpha) or 6 h (all the others). In the mRNA studies, DAMB resulted in an early increase of inflammatory cytokines or chemokines IL-1beta, TNF-alpha, MCP-1, and MIP-1beta (2 to 6 h) and in a late increase of anti-inflammatory IL-1ra (22 h). ABCD showed a general similar trend of inflammatory gene up-regulation. LAMB and ABLC decreased or did not affect IL-1beta and TNF-alpha, whereas ABLC additionally decreased MIP-1beta. In protein measurement studies, DAMB and ABCD up-regulated production of IL-1beta (P < 0.05), decreased the IL-1ra/IL-1beta ratio, and up-regulated the production of MCP-1 and MIP-1beta. In comparison, LAMB and ABLC down-regulated or did not affect the production of these cytokines/chemokines compared to untreated MNCs; furthermore, ABLC tended to increase the IL-1ra/IL-1beta ratio. These studies demonstrate that amphotericin B formulations differentially affect gene expression and release of an array of proinflammatory and anti-inflammatory cytokines that potentially may explain the differences in infusion-related reactions and dose-dependent nephrotoxicity as well as modulation of the host immune response to invasive fungal infections.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15793118      PMCID: PMC1068615          DOI: 10.1128/AAC.49.4.1397-1403.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  44 in total

Review 1.  Cytokine imbalance in the pathogenesis of rheumatoid arthritis: the role of interleukin-1 receptor antagonist.

Authors:  W P Arend
Journal:  Semin Arthritis Rheum       Date:  2001-04       Impact factor: 5.532

Review 2.  Overview of the lipid formulations of amphotericin B.

Authors:  Bertrand Dupont
Journal:  J Antimicrob Chemother       Date:  2002-02       Impact factor: 5.790

Review 3.  Amphotericin B nephrotoxicity.

Authors:  Gilbert Deray
Journal:  J Antimicrob Chemother       Date:  2002-02       Impact factor: 5.790

Review 4.  Review of comparative studies between conventional and liposomal amphotericin B (Ambisome) in neutropenic patients with fever of unknown origin and patients with systemic mycosis.

Authors:  I W Blau; A A Fauser
Journal:  Mycoses       Date:  2000-10       Impact factor: 4.377

Review 5.  Biological role of interleukin 1 receptor antagonist isoforms.

Authors:  W P Arend; C J Guthridge
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 6.  Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.

Authors:  M Tiphine; V Letscher-Bru; R Herbrecht
Journal:  Transpl Infect Dis       Date:  1999-12       Impact factor: 2.228

7.  Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.

Authors:  T J Walsh; R W Finberg; C Arndt; J Hiemenz; C Schwartz; D Bodensteiner; P Pappas; N Seibel; R N Greenberg; S Dummer; M Schuster; J S Holcenberg
Journal:  N Engl J Med       Date:  1999-03-11       Impact factor: 91.245

8.  Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study.

Authors:  T J Walsh; J L Goodman; P Pappas; I Bekersky; D N Buell; M Roden; J Barrett; E J Anaissie
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

Review 9.  Lipid-based amphotericin B: a review of the last 10 years of use.

Authors:  I M Hann; H G Prentice
Journal:  Int J Antimicrob Agents       Date:  2001-03       Impact factor: 5.283

10.  Amphotericin B activation of human genes encoding for cytokines.

Authors:  P D Rogers; J K Jenkins; S W Chapman; K Ndebele; B A Chapman; J D Cleary
Journal:  J Infect Dis       Date:  1998-12       Impact factor: 5.226

View more
  18 in total

1.  Dramatic remission of nephrotic syndrome after unusual complication of mucormycosis in idiopathic membranous nephropathy.

Authors:  Wenling Ye; Yingyi Wang; Yubing Wen; Hang Li; Xuemei Li
Journal:  Int Urol Nephrol       Date:  2014-01-11       Impact factor: 2.370

2.  Synergistic interaction of the triple combination of amphotericin B, ciprofloxacin, and polymorphonuclear neutrophils against Aspergillus fumigatus.

Authors:  Theodouli Stergiopoulou; Joseph Meletiadis; Tin Sein; Paraskevi Papaioannidou; Thomas J Walsh; Emmanuel Roilides
Journal:  Antimicrob Agents Chemother       Date:  2011-09-12       Impact factor: 5.191

3.  Differences in efficacy and cytokine profiles following echinocandin or liposomal amphotericin B monotherapy or combination therapy for murine pulmonary or systemic Aspergillus flavus infections.

Authors:  J A Olson; J Schwartz; D Hahka; A George; R T Proffitt; J P Adler-Moore
Journal:  Antimicrob Agents Chemother       Date:  2011-10-03       Impact factor: 5.191

4.  Experimental central nervous system aspergillosis therapy: efficacy, drug levels and localization, immunohistopathology, and toxicity.

Authors:  Karl V Clemons; Julie A Schwartz; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

5.  Assessment of effective renal plasma flow, enzymuria, and cytokine release in healthy volunteers receiving a single dose of amphotericin B desoxycholate.

Authors:  Manjunath P Pai; Jeffrey P Norenberg; Robert A Telepak; David S Sidney; Shu Yang
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

6.  Impact of different antimycotics on cytokine levels in an in vitro aspergillosis model in human whole blood.

Authors:  Zoe Oesterreicher; Sabine Eberl; Markus Zeitlinger
Journal:  Infection       Date:  2019-08-01       Impact factor: 3.553

7.  Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis.

Authors:  Hsin-Yun Sun; Barbara D Alexander; Olivier Lortholary; Francoise Dromer; Graeme N Forrest; G Marshall Lyon; Jyoti Somani; Krishan L Gupta; Ramon del Busto; Timothy L Pruett; Costi D Sifri; Ajit P Limaye; George T John; Goran B Klintmalm; Kenneth Pursell; Valentina Stosor; Michelle I Morris; Lorraine A Dowdy; Patricia Munoz; Andre C Kalil; Julia Garcia-Diaz; Susan Orloff; Andrew A House; Sally Houston; Dannah Wray; Shirish Huprikar; Leonard B Johnson; Atul Humar; Raymund R Razonable; Shahid Husain; Nina Singh
Journal:  Clin Infect Dis       Date:  2009-12-01       Impact factor: 9.079

Review 8.  Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.

Authors:  Marit D Moen; Katherine A Lyseng-Williamson; Lesley J Scott
Journal:  Drugs       Date:  2009       Impact factor: 9.546

9.  Effects of lipid formulations of amphotericin B on activity of human monocytes against Aspergillus fumigatus.

Authors:  J Dotis; M Simitsopoulou; M Dalakiouridou; T Konstantinou; A Taparkou; F Kanakoudi-Tsakalidou; T J Walsh; E Roilides
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

Review 10.  Amphotericin B formulations: a comparative review of efficacy and toxicity.

Authors:  Richard J Hamill
Journal:  Drugs       Date:  2013-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.